Quick links: Pain • Anemia/Fatigue • Emesis • Mucositis • Neutropenia • Involuntary Weight Loss • Quality Care

Pain

PA-1

Cannabis-Based Medicines in the Treatment of Cancer Pain: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Comparative Study of the Efficacy, Safety, and Tolerability of Sativex and Tetranabinex in Patients With Cancer-Related Pain
Jeremy R. Johnson¹ and Stephen Wright²

¹Severn Hospice, Bicton Heath, Shrewsbury, United Kingdom, and ²GW Pharma Ltd, Salisbury, United Kingdom

PA-2

Assessment of Pain, Other Symptoms, Performance Status and Quality of Life in Children With Non-Hodgkin's Lymphoma (NHL)
Eleonora Mess,¹ Wojciech Leppert,² Adriana Borodzicz-Cedro,¹ and Krzysztof Szmyd³

¹Palliative Care Nursing Department, Public Health Faculty, Medical Academy, Wrocław, Poland; ²Department of Palliative Medicine, Poznan University of Medical Sciences, Poznan, Poland; and ³Department of Paediatric Bone Marrow Transplantation, Oncology and Hematology, Wrocław Medical University, Wrocław, Poland

PA-3

Evaluation and Treatment Recommendations for Taxane-Induced Peripheral Neuropathy in Women with Breast Cancer
Meredith Wampler,^1,2 Ernest Rosenbaum,¹ and Christine Miaskowski³

¹University of California, San Francisco; ²Graduate Program in Physical Therapy, San Francisco State University; and ³Department of Physiological Nursing, University of California, San Francisco

poster

269 kb

Anemia/Fatigue

PA-4

Patient-Reported Fatigue in Three Sunitinib Malate (SU11248) Phase II Trials for the Treatment of Advanced Renal Cell Carcinoma, Gastrointestinal Stromal Tumor, and Neuroendocrine Tumor
Jennifer L. Beaumont,¹ David Cella,¹ Jim Z. Li,² Xin Huang,² Paul Bycott,² Charles Baum,² and the SU11248 GIST, RCC, and NET study teams

¹Center on Outcomes, Research and Education (CORE), Evanston Northwestern Healthcare, Evanston, Illinois, and ²Pfizer Inc., San Diego, California

poster

172 kb

PA-5

Communication Regarding Chemotherapy-Induced Anemia and Related Fatigue: Recommendations From an Observational Linguistic Study
D. Blum,¹ D. Cella,² B. Davidson,³ H. Hamilton,⁴ L. Nail,⁵ and R. Waltzman⁶

¹CancerCare, New York, New York; ²Center on Outcomes, Research and Education (CORE), Evanston Northwestern Healthcare, Evanston, Illinois; ³MBS/Vox, Parsippany, New Jersey; ⁴Georgetown University, Washington, DC; and ⁵Oregon Health and Sciences University, Portland; and ⁶St. Vincent’s Hospital, New York, NY

poster

37 kb

PA-6

The Effectiveness of Darbepoetin Alfa Administered Every 3 Weeks on Clinical Outcomes in Elderly Patients With Chemotherapy-Induced Anemia
Ralph Boccia,¹ Peter Silberstein,² Simon Tchekmedyian,3 Dianne Tomita,⁴ Greg Rossi,⁴ and Greg Otterson⁵ on behalf of the Aranesp Synchronicity (20030206) Study Group

¹Center for Cancer and Blood Disorders, Bethesda, Maryland; ²Creighton University, Omaha, Nebraska; ³Pacific Shores Medical Group, Huntington Beach, California; ⁴Amgen Inc., Thousand Oaks, California; and ⁵Ohio State University, Columbus, Ohio

poster

66 kb

PA-7

Status of Anemia Management in Community Oncology
Barry Fortner, Ling Zhu, and Lee S. Schwartzberg

Accelerated Community Oncology Research Network, Memphis, Tennessee

Emesis

PA-8

Enhanced Pharmacokinetic Profile of Ondansetron Oral Spray
Greg Berk,¹ Arkady Rubin,² and Gavin Choy¹

¹Hana Biosciences, Inc., South San Francisco, California, and ²NovaDel Pharma, Inc., Flemington, New Jersey

PA-9

Post-Marketing Surveillance Data Demonstrate a Favorable Safety Profile of Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Clinical Practice
Michael T. Cullen, Jr.,¹ Mary M. McGuiggan,¹ and Mario Bertazzoli²

¹MGI Pharma Inc., Bloomington, Minnesota, and ²Helsinn Healthcare SA, Lugano, Switzerland

poster

372 kb

PA-10

Control of Chemotherapy-Induced Nausea Remains Suboptimal Despite Widespread Use of Multiple-Day Ondansetron, Dolasetron, or Granisetron Antiemetic Therapy
Jane Hickok, Gary Morrow, and Joseph A. Roscoe

University of Rochester Cancer Center, Rochester, New York

poster

751 kb

PA-11

The Use of the Three-Step Antiemetic Ladder in the Treatment of Chronic Nausea and Vomiting and in the Course of Inoperable Bowel Obstruction in Patients With Advanced Cancer
Wojciech Leppert,¹ Sławomir Paweł Wozniak,² and Jacek Łuczak¹

¹Department of Palliative Medicine, Poznan University of Medical Sciences, Poznan, Poland, and ²Palliative Care Department, Down Silesian Oncology Centre, Wrocław, Poland

PA-12

Improving the Functional Status of Patients With Cancer by More Effectively Preventing Chemotherapy-Induced Nausea and Vomiting (CINV): A Comparison of Palonosetron (PALO) vs Ondansetron (OND) or Dolasetron (DOL)
Carl de Moor¹ and Regina S. Cunningham²

¹Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts, and ²The Cancer Institute of New Jersey, New Brunswick

poster

465 kb

PA-13

Single-Dose Palonosetron is Superior to Single-Dose Ondansetron or Dolasetron in Preventing Emesis in Patients Receiving Highly Emetogenic Chemotherapy (HEC) or Anthracycline-Cyclophosphamide (AC)-Based Chemotherapy for Breast Cancer
Hope S. Rugo¹ and Steven M. Grunberg²

¹University of California San Francisco Comprehensive Cancer Center, San Francisco, and ²University of Vermont, Burlington

poster

582 kb

PA-14

Cost Comparison of Palonosetron to Short-Acting Serotonin Receptor Antagonists (SRAs) for the Prevention of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting (CINV)
Lee S. Schwartzberg¹ and Gordon J. Vanscoy²

¹The West Clinic, Memphis, Tennessee, and ²University Pharmacotherapy Associates, LLC, Monroeville, Pennsylvania

poster

864 kb

Mucositis

PA-15

Palifermin Is Safe and Well Tolerated in Patients With Hematologic Malignancies (HM) Undergoing High-Dose Chemoradiotherapy (HD-CRT) Followed by Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)
B. Blazar,¹ D. Weisdorf,¹ T. DeFor,¹ A. Goldman,¹ S. Silver,¹ and J.L.M. Ferrara2

¹University of Minnesota, Minneapolis, and ²University of Michigan, Ann Arbor

PA-16

Oral Mucositis Incidence and Severity Reduced With AES-14: Results of a Phase III Pivotal Trial in Patients with Breast Cancer
Douglas E. Peterson,¹ and Robert G. Petit II²

¹University of Connecticut Health Center, Farmington, and ²MGI Pharma Inc., Bloomington, Minnesota

poster

480 kb

PA-17

No Difference on Long-Term Disease Outcomes Between Patients With Hematologic Malignancies (HM) Treated with Palifermin in the Autologous Hematopoietic Stem Cell Transplant (HSCT) Setting
P. Stiff,¹ C. Emmanouilides,² U. Gayko,³ Mon-Gy Chen,³ and R. Spielberger⁴

¹Cardinal Bernardin Cancer Center, Maywood, Illinois; ²UCLA Medical Center, Los Angeles, California; ³Amgen Inc, Thousand Oaks, California; and ⁴City of Hope National Medical Center, Duarte, California

PA-18

A Patient Self-Reported Daily Questionnaire Is a Feasible and Valid Tool in Oral Mucositis in Patients With Hematologic Malignancies Undergoing High-Dose Chemoradiotherapy (CRT) with HSCT
Patrick J. Stiff,¹ William I. Bensinger,² Christos Emmanouilides,³ Z. John Lu,⁴ Alessandra Cesano,⁴ and Ricardo Spielberger⁵

¹Loyola University, Maywood, Illinois; ²Fred Hutchinson Cancer Research Center, Seattle, Washington; ³UCLA David Geffen School of Medicine, Los Angeles, California; ⁴Amgen, Inc., Thousand Oaks, California; and ⁵City of Hope National Medical Center, Duarte, California

Neutropenia

PA-19

Pegfilgrastim Use in Older Patients (> 60 Years) Maintains Dose Intensity of Dose-Dense Adjuvant Chemotherapy for Early-Stage Breast Cancer
R.E. Birhiray, R.T. Schmidt, J. Powell, R.M. Harwood

Hematology-Oncology of Indiana, PC, Indianapolis, Indiana

poster

389 kb

PA-20

Patterns of Care and Incidence of Neutropenia-Related Complications During Chemotherapy and the Use of Pegfilgrastim and Filgrastim in Community Practice: Results of the ACCEPT Study
Luis T. Campos,¹ Mitchell H. Folbe,² Veena Charu,³ Jennifer Malin,⁴ Beiying Ding,⁴ and Roger Dansey⁴

¹Oncology Consultants, P.A., Houston, Texas; ²Medical Oncology, Troy, Michigan; ³Pacific Cancer Medical Center, Inc., Anaheim, California; and ⁴Amgen Inc., Thousand Oaks, California

PA-21

Pegfilgrastim in All Cycles Reduces Chemotherapy-Induced Neutropenia in Older Patients
W. Ershler,¹ T. Pluard,² N. Angel,³ S. Shahin,⁴ J. Green,⁴ R. Dansey,⁴ and L. Balducci⁵

¹Institute for Advanced Studies in Aging, Washington, DC; ²Missouri Cancer Care PC, Saint Charles, Missouri; ³Oncology Center at Providence Park, Mobile, Alabama; ⁴Amgen Inc., Thousand Oaks, California; ⁵Moffitt Cancer Center and Research Institute, Tampa, Florida

PA-22

Impact of First and Subsequent Cycle Pegfilgrastim on Neutropenic Events in Patients Receiving Myelosuppressive Chemotherapy: Preliminary Results of FIRST, a Prospective Community-Based Study
Howard Ozer,¹ Beiying Ding,² and Roger Dansey,²

¹University of Oklahoma Cancer Center, Oklahoma City, and ²Amgen Inc., Thousand Oaks, California

PA-23

Neutropenia and Anxiety in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients: Initial Report of a Randomized, Controlled, Pilot Trial Using Pegfilgrastim to Reduce Neutropenia Complications
F. Smith,¹ L. Wagner,² M. Kandahari,³ S. Shahin,³ J. Malin,³ R. Dansey,³ and J. Crawford⁴

¹Sibley Memorial Hospital, Washington, DC; ²Northwestern University, Feinberg School of Medicine, Chicago, Illinois; ³Fairfax Hospital Cancer Center, Fairfax, Virginia; and ³Amgen, Thousand Oaks, California; 4Duke University Medical Center, Durham, North Carolina

Involuntary Weight Loss

PA-24

Cost-Utility Analysis: Oxandrolone Versus No Treatment for Cancer-Related Weight Loss
Hind T. Hatoum^1,2 and A. Simon Pickard²

¹Hind T. Hatoum & Company, Chicago, Illinois, and ²University of Illinois, College of Pharmacy, Chicago

PA-25

A Pilot Limited Institutional Study to Evaluate the Safety and Tolerability of Immunocal, a Nutraceutical Cysteine Delivery Agent in the Management of Wasting in High-Risk Childhood Cancer Patients
Steven J. Melnick,¹ Paul Rogers,² Nancy Sacks,³ Thomas A. Kwyer,⁴ Jacqueline Halton,⁵ Eric Sandler,⁶ Enrique Escalon,⁷ and Elena J. Ladas⁸

¹Department of Pathology and Laboratories, Miami Children's Hospital. Miami, Florida; ²Division of Paediatric Haematology/Oncology & Bone Marrow Transplantation, C&W Hospital and University of BC, Vancouver, British Columbia, Canada; ³Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; ⁴Division of Otolaryngology, Department of Surgery, Medical University of Ohio, Toledo, ⁵Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada; ⁶Nemours Children's Clinic-Jacksonville Hematology/Oncology, Jacksonville, Florida; ⁷Division of Hematology/Oncology, Miami Children's Hospital, Miami, Florida; and ⁸Integrative Therapies Program for Children with Cancer, Columbia University, New York, New York

PA-26

Psychosocial and Dietary Management of Anorexia by Patients with Advanced Cancer
Jeremy E. Shragge,^1,2 Kärin Olson,² Wendy Wismer,¹ and Vickie Baracos³

¹Department of Agricultural, Food and Nutritional Sciences, ²International Institute for Qualitative Methodology, and ³Department of Oncology, University of Alberta, Edmonton, Alberta, Canada

Quality Care

PA-27

Psychosocial Outcomes of Prostate Cancer Survivors on Androgen-Deprivation Therapy
Sylvie Aubin

Department of Psychiatry and Behavioral Medicine, University of Washington, Seattle

PA-28

The Use and Delivery of Emergency Drug Kits (EDKs) at the Birmingham VA Medical Center: A Multidisciplinary Quality Improvement Project Using the Plan-Do-Study-Act (PDSA) Cycle
Joseph T. Chan,^1,2 Heather D. Au,¹ J. Andrew Carr,¹ James T. Coleman,¹, Debra Cook-Rice,¹ and Frank Amos Bailey^1,2

¹Birmingham VA Medical Center, Birmingham, Alabama, and ²University of Alabama at Birmingham Center for Palliative Care, Birmingham

PA-29

Item Validation of Patient Care Monitor Version 2 (PCM2.0) Using Nursing Interview and PCM1.0
Barry V. Fortner, Lee S. Schwartzberg, and Arthur C. Houts

Supportive Oncology Services, Memphis, Tennessee; The West Clinic, Memphis Tennessee

PA-30

Patient-Reported Symptom Complaints Associated with 5-Fluorouracil (5-FU) + Irinotecan (IRI) or Oxaliplatin (OXALI) in Colorectal Cancer (CRC)
Barry Fortner,¹ Kimary Kulig,² Ling Zhu,¹ Samuel Wagner,² Johnetta Blakely,³ and Lee Schwartzberg³

¹Accelerated Community Oncology Research Network, Memphis, Tennessee, and ²Pfizer Outcomes Research, New York, New York, 3The West Clinic, Memphis, Tennessee

PA-31

Validation of the Functional Assessment of Cancer Therapy-Brain (FACT-Br) Questionnaire and FACT-Br Symptom Index (FBrSI) in Patients with Recurrent High-Grade Gliomas
Angel Nickolov,¹ Jennifer L. Beaumont,¹ David Victorson,¹ Amy H. Peterman,² David Cella,¹ Astra M. Liepa,³ and Howard A. Fine⁴

¹Center for Outcomes, Research and Education (CORE), Evanston Northwestern Healthcare, Evanston, Illinois; ²University of North Carolina, Charlotte, North Carolina; ³Eli Lilly and Company, Indianapolis, Indiana; and ⁴Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

poster

65 kb

PA-32

The Life Tape Project, An Existential Intervention for Cancer Patients: A Progress Report
Ernest Rosenbaum,¹ Robert W. Garlan,² Alison L. Siegel,³ Shelly Henderson,⁴ Naama Hirschberger,⁵ Lisa D. Butler,⁶ and David Spiegel⁶

¹Department of Medical Oncology and the Comprehensive Cancer Center, University of California, San Francisco; ²Private Practice, San Jose, California; ³Breast Cancer Clinic and Resource Center, University of California, San Francisco; ⁴Pacific Graduate School of Psychology, Palo Alto, California; ⁵The Sharett Institute of Oncology, Hadassah University Medical Center, Jerusalem, Israel; and ⁶Department of Psychiatry & Behavioral Sciences, Stanford University School of Medicine, Stanford, California

poster

341 kb

© 2006 by Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

The opinions expressed herein are those of the authors or advertisers. The authors, editors, and publishers make every effort to ensure that no inaccurate or misleading data, opinion, or statement is published in this journal and that drug names, dosages, and recommendations are accurate. However, readers should confirm all dosage schedules against the manufacturer’s package information data. The Publisher, Editorial Board, and their employees accept no liability whatsoever for the consequences of any inaccurate or misleading data, opinion, or statement.